Coronavirus-treatment-updates
The U.S. Food and Drug Administration
authorizes bamlanivimab and
etesevimab, administered together, to include emergency use as post-exposure
prophylaxis (prevention) for COVID-19 in adults and pediatric patients (12
years of age and older weighing at least 40 kg) who are at high risk for
progression to severe COVID-19, including hospitalizat...
Novel Coronavirus (COVID-19)
Guidelines of Bangladesh.
The guidelines for the diagnosis,
treatment, and control of the coronavirus disease (COVID-19).
The U.S. Food and Drug
Administration issued an emergency use authorization (EUA) for
bamlanivimab and etesevimab administered together for the treatment of mild to
moderate COVID-19.
In a clinical trial of patients
with COVID-19 at high risk for disease progression, a single intravenous
infusion of bamlanivimab and etesevimab administe...
The Pharmacovigilance Risk
Assessment Committee (PRAC) of the European Medicines Agency (EMA) has
recommended adding sinus bradycardia to the product label for
remdesivir as an adverse reaction of "unknown frequency."As part of its review, the
committee examined all the available data on "rare" reported cases of
bradycardia in patients, who re...
Ivermectin is an antiparasitic
drug that is approved by the Food and Drug Administration (FDA) for the
treatment of onchocerciasis and strongyloidiasis. Ivermectin is not
FDA-approved for the treatment of any viral infection. In general, the drug is
well tolerated. It is currently being evaluated as a potential treatment for
COVID-19.
Iverm...
The COVID-19 Treatment Guidelines have been developed to
inform clinicians how to care for patients with COVID-19. Because clinical
information about the optimal management of COVID-19 is evolving quickly.
The recommendations in these Guidelines are based on scientific
evidence and expert opinion. Each recommendation includes two...
This guidance document is
intended for clinicians caring for COVID-19 patients during all phases of their
disease (i.e., screening to discharge). This update has been expanded to
meet the needs of front-line clinicians and promotes a multi-disciplinary
approach to care for patients with COVID-19, including those with mild,
moderate, severe, a...
In patients with severe or critical Coronavirus disease 2019 (COVID-19) manifestations, a thromboinflammatory syndrome, with diffuse microvascular thrombosis, is increasingly evident as the final step of pro-inflammatory cytokines storm. Actually, no proven effective therapies for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) i...
In a clinical trial of patients with COVID-19, monoclonal antibody were shown to reduce COVID-19-related
hospitalization or emergency room visits in patients at high risk for
disease progression within 28 days after treatment when compared to
placebo. The safety and effectiveness of this investigational therapy
for use in the treatment of C...
FDA Authorizes Monoclonal Antibody for Treatment of COVID-19. The U.S. FDA issued an emergency use authorization (EUA)
for the investigational monoclonal antibody therapy for
the treatment of mild-to-moderate COVID-19 in adult and pediatric
patients.
Dexamethasone : the first life-saving drug for COVID-19 patients
Clinical trials make it possible to
evaluate whether a treatment improves outcomes. Developing a hypothesis,
for example if treatment A is better than standard treatment B,
clinical trials enable understanding of the role of an intervention in
improving patient care. In the...
Baricitinib plus remdesivir was superior to remdesivir alone in reducing
recovery time and accelerating improvement in clinical status among
patients with Covid-19, notably among those receiving high-flow oxygen
or noninvasive ventilation. The combination was associated with fewer
serious adverse events.
